-18 percent.. really, lol !24 Jan 2022 11:37
The outlook suggests a climb from today's sp ...
Broker note out ...
A solid update reveals that trading to Dec-21 is expected to be in line - both on revenue and EBITDA, while FCF should be materially better. This implies +13% organic top-line growth to £59.1m (on a 12mth basis) most notably driven by resurgent hardware sales (+20% y/y) as trading recovered strongly post Covid. Meanwhile, ARR continues to grow – now £39.0m, so +13% annualised since June. Driving this, SAAS added >65 new customers, whilst also grew key relationships like JCB, meaning the Group’s subscription base grew 10% to 0.55m. EBITDA is also better at £7.6m (vs. £6.5m in cal’20) despite higher S&M costs to drive international growth. The strong aforementioned OEM progress, as well as improved cash collection, flowed through to FCF, as y/e net cash of £13.4m implies £6.1m FCF (materially better than £3.4mE). On outlook, SAAS continues to see a “healthy pipeline”, though caution that supply chain challenges could last longer than expected. In response, we therefore trim FY22E&23E – believing that c.10% revenue growth is now more realistic, while also offers upgrade potential should component shortages become less acute.
Microlise has become the UK market leader as it offers an unrivalled suite of mission critical logistics software to the largest (and most complex) operators, and together with ‘network effects’ and excellent customer service, more and more customers choose to join Microlise every year. In addition - by upselling and cross-selling its ever expanding product portfolio - Microlise tends to increase its penetration with existing customers and in-so-doing, typically achieves NRR well above 100%...
Offering solutions that unlock efficiency, save costs and address growing ESG considerations, we continue to see a very healthy demand environment across Microlise’s current and prospective customer base, meaning the long-term picture remains very encouraging. This said - with hardware sales still key (27%/sales) – prolonged component shortages have become a constraint and an unavoidable challenge. As such, we have taken the prudent view to trim FY22&23E sales by 5%, with this flowing through to EBITDA and FCF.
Within this, recurring software revenue (which is increasingly hardware independent) should fare best – we revise this down just 300bps ~+13% y/y growth in ’22.....with upgrade potential should component shortages become less acute.